Work

Treatment Options for Relapsed and Refractory Multiple Myeloma

Year: 2011

Type: review

Abstract: Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these treatment approaches are being tested in phase I, II, and III clinical trials, with the goal of prolonged duration of remission and, ultimately, improved overall survival.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-10-1805

Authors: Sagar Lonial, Constantine S. Mitsiades, Paul G. Richardson

Institutions: Emory University, Dana-Farber Cancer Institute, Winship Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: U.S. Food and Drug Administration